Mineralys Therapeutics
Latest round
- Series B
Last raised
- Jun 2022
Total raised
- $161M
Investors
- 13
About Mineralys Therapeutics
Founded in 2020 and based in Pennsylvania, US, Mineralys Therapeutics, Inc. operates as a biopharmaceutical company that provides therapy for patients with hypertension. In February 2024, Mineralys Therapeutics, Inc. The clinical-stage biopharmaceutical company develops targeted therapies for diseases driven by elevated aldosterone levels. The company prioritizes tackling the substantial medical issue of hypertension, aiming to reduce the economic costs and health implications linked with poorly managed high blood pressure. Mineralys Therapeutics' flagship product, Lorundrostat, is a highly selective aldosterone synthase inhibitor designed to specifically target and reduce elevated aldosterone levels without affecting cortisol, offering a therapeutic approach for patients with aldosterone-dependent hypertension. With clinical results from phase 2 trials demonstrating both efficacy and safety, Mineralys represents a pivotal advancement in hypertension treatment.
Who invested in Mineralys Therapeutics
13 investors across 3 rounds
See all investors in Mineralys Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Mineralys Therapeutics
Who invested in Mineralys Therapeutics?
Mineralys Therapeutics has 13 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Mineralys Therapeutics raised?
Mineralys Therapeutics has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did Mineralys Therapeutics last raise money?
Mineralys Therapeutics's most recent round on record is a Series B, in Jun 2022.
What does Mineralys Therapeutics do?
Founded in 2020 and based in Pennsylvania, US, Mineralys Therapeutics, Inc.
Where is Mineralys Therapeutics headquartered?
Mineralys Therapeutics is headquartered in Radnor, US.
Which VCs invest in companies like Mineralys Therapeutics?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Mineralys Therapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Mineralys Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.